How will the Israel-Hamas war impact pharma manufacturers?
Some companies operating in Israel have already closed their businesses in the region for security reasons.
25 October 2023
25 October 2023
Some companies operating in Israel have already closed their businesses in the region for security reasons.
At the ongoing CpHI Europe meeting, experts outline the key elements that will be expected in future pharma partnerships.
A panel discussion at a Copenhagen conference saw representatives from sponsor organisations sharing their hopes for CROs to take ownership when trials go wrong.
Sponsors have been encouraged to keep their reputations above water and stave off bureaucratic slowdown to clinical trials by meeting clinicians face to face.
AstraZeneca will pay $75m to Daiichi Sankyo as a milestone payment following the latest EU approval to treat NSCLC patients with a HER2 mutation.
The FDA released a draft guidance giving firms recommendations on provider-directed communication for off-label drug use.
Amidst a changing, complex Covid-19 marketplace, HDT-Bio looks towards harnessing multivalence for its Covid-19 candidate, HDT-301.
The funds will go towards Phase II trials for the company’s two candidates treating seborrheic keratoses and melasma.
Although metaverse technologies could reinvent healthcare approaches and bring new experiences to healthcare providers and patients, adoption is still at an early stage. There are currently few use cases in the healthcare industry. The metaverse needs to overcome major challenges for healthcare, including regulation and data privacy concerns. Evidence of proven use cases and participation by a critical mass of users are imperative to drive a shift in metaverse investment.
Join us on November 1st as Cynthia Bheling, Zobair Younossi, Rohit Loompa, and Vipul Jairath provide an overview of the drug development landscape.
Give your business an edge with our leading industry insights.